Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse

Figure 2 Hepatic and serum fat content reduced by TCPOBOP treatment in the MCD diet-fed mice. (A) Top panel, from left to right: Fixed liver specimens from vehicle-treated chow-fed mice, TCPOBOP-treated (3 mg/kg ip for 3 d) chow-fed mice, vehicle-treated (corn oil) MCD diet-fed diet mice for 2 wk, TCPOBOP-treated MCD diet-fed mice for 2 wk; CAR inhibitor, androstanol-treated MCD diet-fed mice for 2 wk were stained by conventional H&E. Lower panel: Quantitation of hepatic fat content by Oil red O staining. Note the marked reduction of hepatic fat in the TCPOBOP-treated MCD diet-fed mice (^bP = 0.001); (B) Serum triglyceride levels from mice fed the MCD diet for 2 wk with either TCPOBOP or androstanol treatment. Treatment with TCPOBOP reduced serum triglyceride levels by half (^aP = 0.03).